Parkinsons Progression Markers Initiative Clinical Study Tracking Parkinsons Disease Progression and Healthy Controls

What this Trial Is About

Researchers are conducting the Parkinsons Progression Marker Initiative PPMI, a large, multi-center, observational study to track the progression of Parkinsons disease PD over time. This study includes participants with diagnosed PD, those at risk prodromal PD, and healthy controls. It aims to identify markers related to PD progression by collecting clinical, digital, imaging, biological, and genetic data, which could help in developing therapies to slow PD disability progression. PPMI Clinical plans to enroll up to 4,500 participants who will be followed for 5 to 8 years. Participants may also be invited to join additional related programs such as PPMI Remote, PPMI Digital App, or PPMI Online, depending on their recruitment method and cohort classification. The study collects a wide range of data including clinical assessments, digital outcomes, imaging scans, biological samples, and genetic testing. Participants may undergo repeated evaluations, including imaging tests like SPECT, and provide information through questionnaires and digital tools. Throughout the study, participants will attend visits at regular intervals to undergo assessments that help researchers measure disease progression and compare changes over time. Data collected includes clinical signs, imaging results, biological markers, and genetic information. The study also monitors the probability of disease development in at-risk individuals. The overall duration of participation can extend up to 13 years, ensuring comprehensive long-term data collection and safety monitoring.

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort